Samsung Biologics

Samsung Biologics engages suppliers to advance global decarbonization targets

Retrieved on:

화요일, 11월 28, 2023

COP26, Carbon, Climate change, TCFD, CDMO, Samsung Biologics, Patient, KRX, Health, Supply, Task force, SMI, Partnership, ESG, Samsung, Renewable energy, Songdo

The company invited supplier companies and external ESG specialists to discuss ESG-related requirements and recommendations as well as share successful case studies.

Key Points:

The company invited supplier companies and external ESG specialists to discuss ESG-related requirements and recommendations as well as share successful case studies.
"Since a majority of healthcare emissions are created in the manufacturing supply chains, it is critical for us to work together at every level to become greener and more circular," said John Rim, CEO and President of Samsung Biologics.
Samsung Biologics has been conducting ESG assessments with its suppliers to minimize potential social and ethical risks, build a stable network, and establish green strategies towards decarbonization.
Highlights from the 2023 report include:
Prioritizing Samsung Biologics' sustainable leadership as an active member of the Sustainable Markets Initiative and champion for the Supply Chains Working Group; First CDMO to receive the SMI's Terra Carta Seal

Samsung Biologics appoints new leadership to oversee quality and regulatory affairs

Retrieved on:

목요일, 8월 24, 2023

KRX, GSK plc, Chronic kidney disease, Head, Fujifilm Diosynth Biotechnologies, Samsung, Samsung Biologics, Quality, CDMO, Ward, Micro Focus Quality Center, Regulatory affairs, Celltrion, Pharmaceutical industry, Biogen

INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

Key Points:

- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation.
INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.
Prior to joining Samsung Biologics, Ward served as Head of Quality at ProKidney Corporation, a late clinical-stage biotech company specializing in treatments for chronic kidney disease.
Samsung Biologics also appointed Sojeong Lee as the Vice President and Head of Regulatory Affairs to oversee and manage the company's response to and relationship with global regulatory agencies.

Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility

Retrieved on:

화요일, 7월 18, 2023

KRX, RE100, Nature, World Health Organization's response to the COVID-19 pandemic, SMI, Samsung, United Nations Global Compact, Samsung Biologics, Carbon, Social Security Government Pension Offset, Organization, CDMO, Growth, ESG, Social, Annual report, Environment, Renewable energy, Mobile phone

INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.

Key Points:

INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report.
"Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the wider community," said John Rim, President and CEO of Samsung Biologics.
Samsung Biologics also hosted representatives from the World Health Organization's human resource training hub to offer biologics development and manufacturing courses.
"Samsung Biologics is engaged in this work because we want to leave the world better than we found it," Rim added.

Samsung Bioepis Releases 2023 Sustainability Report

Retrieved on:

금요일, 6월 30, 2023

Social responsibility, RE100, COVID-19, Samsung, Research, Samsung Biologics, Sustainability accounting, Climate change, GRI, Patient, Sustainability Accounting Standards Board, Ethics, Growth, ESG, R, Annual report, Environment, Pharmaceutical industry, Renewable energy

The annual report provides a comprehensive overview of Samsung Bioepis’ performance and management of the company’s commitment to sustainability, and key highlights of the report are as follows:

Key Points:

The annual report provides a comprehensive overview of Samsung Bioepis’ performance and management of the company’s commitment to sustainability, and key highlights of the report are as follows:
Samsung Bioepis pursues transformation and innovation throughout its business activities to drive its sustainable growth and to help address important issues that matter to our business, our stakeholders and society.
Ensuring product quality and patient safety are at the center of Samsung Bioepis’ vision and priorities.
Samsung Bioepis has rigorous quality management system in compliance with global standards to prevent quality risks.
Samsung Bioepis’ detailed ESG performance can be found in the full report: https://bit.ly/3NR2obo

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

Retrieved on:

화요일, 6월 6, 2023

Communication, Electronic Dream Plant, Samsung Biologics, Innovation Center station, Plant, CDMO, Novosibirsk Thermal Power Plant 5, United States Air Force Plant 4, Rare-earth element, Fine chemical, Renewable energy

INCHEON, South Korea, June 6, 2023 /PRNewswire/ -- While attending the 2023 BIO International Convention, Samsung Biologics (KRX:207940.KS), a leading contract development and manufacturing organization (CDMO), revealed details of the company's future expansion plan to have its new fifth plant operational by April 2025. Recently on June 1, the company fully completed its latest and the world's largest biomanufacturing plant, Plant 4. The move reinforces Samsung Biologics' unmatched speed and commitment to providing partners with high-quality services and products in response to the surging demand for biologics.

Key Points:

Recently on June 1, the company fully completed its latest and the world's largest biomanufacturing plant, Plant 4.
The move reinforces Samsung Biologics' unmatched speed and commitment to providing partners with high-quality services and products in response to the surging demand for biologics.
The new plant will add a capacity of 180,000 liters, and upon its completion, Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters.
Plant 5 ultimately marks the first phase of Samsung Biologics' second Bio Campus.

Samsung Biologics Reports First Quarter 2023 Financial Results

Retrieved on:

월요일, 4월 24, 2023

KRX, KRW, Partnership, Development, CDMO, Samsung, PPA, Novosibirsk Thermal Power Plant 5, United States Air Force Plant 4, Samsung Biologics, Semiconductor, Renewable energy, Pharmaceutical industry

INCHEON, South Korea, April 24, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2023.

Key Points:

INCHEON, South Korea, April 24, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2023.
For the first quarter 2023, Samsung Biologics recorded a consolidated revenue of KRW 720.9 billion and an operating profit of KRW 191.7 billion.
First quarter 2023 net profit reached KRW 141.8 billion, a slight decrease from KRW 146.9 billion in the first quarter a year ago due to the elimination of intercompany transactions and PPA amortization after the inclusion of Samsung Bioepis.
On a standalone basis, Samsung Biologics reported KRW 591.0 billion in revenue in the first quarter 2023, attributable to new and extended manufacturing deals.

Araris Biotech AG Announces Strategic Investment with Samsung Ventures

Retrieved on:

수요일, 4월 12, 2023

KRX, Samsung Biologics, Antibody, Solubility, ADC, Spacecraft, Pharmaceutical industry, Fine chemical, Samsung

AU ZH, Switzerland, April 11, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Samsung Venture Investment Corporation (“Samsung Ventures”), an investment corporation established to promote the development of new technologies, has invested in the Company in an independent deal ahead of its on-going series A funding.

Key Points:

AU ZH, Switzerland, April 11, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Samsung Venture Investment Corporation (“Samsung Ventures”), an investment corporation established to promote the development of new technologies, has invested in the Company in an independent deal ahead of its on-going series A funding.
The investment was made via Samsung Life Science Fund – created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures – which reflects Samsung’s commitment to further explore and expand various business opportunities in biopharmaceuticals.
Samsung, as a strategic investor, will collaborate on evaluating, manufacturing and developing assets with Araris using the Company’s proprietary ADC Technology, in close collaboration with Samsung affiliates involved in the discovery and development, and manufacturing of novel biologics.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, CEO of Samsung Biologics.

GC Cell and New Management Embarking on a New Chapter

Retrieved on:

월요일, 4월 3, 2023

During the meeting, GC Cell reported key financial results of the Year 2022 based on consolidated financial statements.

Key Points:

During the meeting, GC Cell reported key financial results of the Year 2022 based on consolidated financial statements.
The company achieved sales revenue of 236.1 billion won, an operating profit of 44.3 billion won, and a net profit of 24.2 billion won.
"2023 will mark a new beginning for GC Cell, determining sustainable growth of our business", said James Park, the new CEO.
GC Cell is a biotechnology company investing in R&D of Cell and Gene Therapies based on NK cells, T cells, and stem cells.

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

Retrieved on:

금요일, 3월 17, 2023

KRX, Samsung Biologics, KRW, Growth, Communication, CDMO, Samsung, Plant, Fine chemical, Rare-earth element

Located near its current Songdo site, Plant 5 will be the first facility of the company's second Bio Campus, encompassing an area of 96,000m2 and holding a capacity of 180,000 liters.

Key Points:

Located near its current Songdo site, Plant 5 will be the first facility of the company's second Bio Campus, encompassing an area of 96,000m2 and holding a capacity of 180,000 liters.
Upon Plant 5's full completion, Samsung Biologics will maintain its global biomanufacturing capacity leadership with a total of 784,000 liters.
Samsung Biologics purchased 360,000m2 of land in July 2022 for its second Bio Campus, which will house additional large-scale plants and an open innovation center.
In line with the company's expansion plans, Samsung Biologics will also enhance its presence in the U.S. with the opening of a regional office in New Jersey next week.

Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development

Retrieved on:

수요일, 1월 25, 2023

Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.

Key Points:

Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.
Taleen Barsoumian will lead Forge’s client development strategy and new business operations across Forge’s suite of manufacturing solutions.
Adam Davis leads the in-house analytical development and testing team supporting clients throughout product development and manufacturing.
Dr. Davis joined Forge in 2020 after 15 years of experience in recombinant adeno-associated viral (AAV) vector product development, process development, and manufacturing.